Skip to main content
OpenTrials
Completed

NCT Number: NCT00831025

Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Olea Europaea Pollen

The objective of this trial is to assess the clinical efficacy of a modified allergen extract of Olea europaea pollen in the treatment of patients affected by allergic rhinitis/rhinoconjunctivitis (with or without episodic asthma) induced by hypersensitivity to olea europaea pollen, evaluating the Score regarding Symptoms and consumption of the medication.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Hospital El Tomillar, Dos Hermanas, Sevilla, Spain

Loading trial locations.

About this study

Immunotherapy is a specific treatment for allergic diseases. Unlike conventional pharmacological treatment, immunotherapy is the only treatment that could modify the natural course of allergic disease. This is a prospective double-blind placebo-controlled study with two arms of treatment: placebo and active.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Prior to study specific examinations the patient and if applicable both legal guardians has to give his/her written informed consent
  • Patients of both gender aged from 18 and 55 years
  • Patient's perception of disease activity of at least 30 mm on a 100 mm visual analogue scale (VAS)
  • FEV1 greater or equal than 80% of the expected value, and if not, improvement of FEV1 greater than 12% after bronchodilation
  • Patients have to suffer from allergic complaints (rhinitis and/or rhinoconjunctivitis with or without mild intermittent allergic asthma) caused by clinical sensitization against Olea europaea pollen. The IgE mediated sensitization has to be verified by:
  • Suggestive medical history
  • Specific IgE against Olea europaea pollen CAP RAST ≥0.7Ku/l
  • Positive skin prick test (SPT) to grass Olea pollen resulting in a wheal diameter of at least 3 mm.

Exclusion criteria

  • History of significant clinical manifestations of allergy as a result of sensitization against weed pollen allergens and perennial (e.g. house dust mite.
  • Participation in an immunotherapy with comparable extracts within the last five years.
  • Treatment with β-blocker
  • Any disease which prohibits the use of adrenaline (e.g. hyperthyroidism)
  • Cardiovascular insufficiency or any severe or unstable pulmonary, or endocrine disease; clinically significant renal or hepatic disease or dysfunction; hematologic disorder; any other clinically significant medical condition that could increase the risk to the study participant
  • Immunopathological diseases
  • Patients who are expected to be non-compliant and/or not co-operative
  • Women, where pregnancy is defined as the state of a female after conception and until the termination of gestation

Treatment and study plan

Immunotherapy with modified extract of Olea europaea pollen

Biological

Subcutaneous immunotherapy with modified extract of Olea europaea. A subcutaneous monthly treatment.

Placebo

Biological

Placebo for subcutaneous monthly administration

Primary outcomes

  1. Symptoms and medication score

    Time frame: 2 years

Secondary outcomes

  1. Dose-response skin prick-test

    Time frame: 2 years

  2. Medication score

    Time frame: 2 years

  3. Rhinoconjunctivitis quality of life questionnaire

    Time frame: 2 years

  4. Visual Analog Scales (VAS)

    Time frame: 2 years

  5. Serology

    Time frame: 2 years

  6. Symptoms score

    Time frame: 2 years

  7. Exhaled nitric oxide

    Time frame: 2 years

  8. Adverse event

    Time frame: 2 years

Sponsors and collaborators

Lead sponsor

Laboratorios Leti, S.L.

Industry

Registry information

Official study title

Multicenter, Randomised, Double-blind Placebo-controlled, Subcutaneous Immunotherapy Clinical Trial With Depigmented and Polymerized Allergen Extract of Olea Europaea Pollen in Patients With Hypersensitivity to Olea Pollen

Acronym: OLEA

Important dates

Study start
2008
Primary completion
2013
Study completion
2013
First posted
Jan 28, 2009
Registry last updated
Feb 23, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.